Steven J. Romano

CIK: 0001639860

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

DNTH

Dianthus Therapeutics, Inc. /DE/

Director

SLN

Silence Therapeutics plc

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

DNTH
Dianthus Therapeutics, Inc. /DE/
May 21, 2026
Award(A)
Stock Option (Right to Buy)
Direct
6.1K shares-
SLN
Silence Therapeutics plc
Jan 2, 2026
Award(A)
Employee Share Option (Right to Buy)
Direct
300K shares-
DNTH
Dianthus Therapeutics, Inc. /DE/
May 22, 2025
Award(A)
Stock Option (Right to Buy)
Direct
12.5K shares-
SLN
Silence Therapeutics plc
Jan 2, 2025
Award(A)
Employee Share Option (Right to Buy)
Direct
285K shares-
DNTH
Dianthus Therapeutics, Inc. /DE/
Sep 16, 2024
Award(A)
Stock Option (Right to Buy)
Direct
22K shares-

		Type	Shares	Price		Ownership
May 21, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	6,090	-	-	Direct
Jan 2, 2026	SLN Silence Therapeutics plc	Award(A) Employee Share Option (Right to Buy)	300,000	-	-	Direct
May 22, 2025	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	12,500	-	-	Direct
Jan 2, 2025	SLN Silence Therapeutics plc	Award(A) Employee Share Option (Right to Buy)	285,000	-	-	Direct
Sep 16, 2024	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	22,000	-	-	Direct

1-5 of 5 transactions

About Romano Steven J.

Romano Steven J. (SEC CIK 0001639860) files insider reports with the SEC as Director of Dianthus Therapeutics, Inc. /DE/ (DNTH) and EVP and Chief R&D Officer of Silence Therapeutics plc (SLN).

Signal8 holds 7 ownership filings by Romano Steven J. (2 Form 3, 5 Form 4), filed between Sep 18, 2024 and May 22, 2026. Those filings report 5 transactions, from Sep 16, 2024 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Romano Steven J.'s filings is in LONDON, X0.

Recent filings by Romano Steven J.

May 21, 2026: Grant or award of DNTH derivative securities (Form 4, code A).
Jan 2, 2026: Grant or award of SLN derivative securities (Form 4, code A).
May 22, 2025: Grant or award of DNTH derivative securities (Form 4, code A).
Jan 2, 2025: Grant or award of SLN derivative securities (Form 4, code A).
Sep 16, 2024: Grant or award of DNTH derivative securities (Form 4, code A).

Other insiders filing for Dianthus Therapeutics, Inc. /DE/ (DNTH)

CARR EDWARD, CHIEF ACCOUNTING OFFICER
Randhawa Simrat, EVP, Head of R&D
Read Simon, Director
Veness Adam M, SVP, General Counsel and Sec.
McGeorge Anne, Director
Garcia Marino, CEO AND PRESIDENT

How to read Form 4 transaction codes